Activating mutations in JAK1 and JAK3 are predominantly found in T-ALL (6.5–27% and 10–16%, respectively), and most frequently in T-PLL (8–12.5% and 30–42%, respectively) [3,4]. The gene discussed is JAK3; the disease is acute lymphoblastic leukemia.